ATE300952T1 - Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem - Google Patents
Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystemInfo
- Publication number
- ATE300952T1 ATE300952T1 AT00984018T AT00984018T ATE300952T1 AT E300952 T1 ATE300952 T1 AT E300952T1 AT 00984018 T AT00984018 T AT 00984018T AT 00984018 T AT00984018 T AT 00984018T AT E300952 T1 ATE300952 T1 AT E300952T1
- Authority
- AT
- Austria
- Prior art keywords
- central nervous
- nervous system
- administration
- active ingredients
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20070899P | 1999-12-09 | 1999-12-09 | |
PCT/US2000/033220 WO2001041782A2 (en) | 1999-12-09 | 2000-12-08 | Method for administering a cytokine to the central nervous system and the lymphatic system |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE300952T1 true ATE300952T1 (de) | 2005-08-15 |
Family
ID=22742853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00984018T ATE300952T1 (de) | 1999-12-09 | 2000-12-08 | Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem |
Country Status (10)
Country | Link |
---|---|
US (3) | US20010043915A1 (de) |
EP (1) | EP1237567B1 (de) |
JP (1) | JP2003516360A (de) |
AT (1) | ATE300952T1 (de) |
AU (1) | AU783208B2 (de) |
CA (1) | CA2393688A1 (de) |
DE (1) | DE60021760T2 (de) |
IL (1) | IL150109A0 (de) |
NO (1) | NO20022731L (de) |
WO (1) | WO2001041782A2 (de) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060024270A1 (en) * | 2000-08-23 | 2006-02-02 | The New York Hospital Medical Center Of Queens | Compositions and methods for preventing or treating encephalitis with interferon |
US6589591B1 (en) * | 2001-07-10 | 2003-07-08 | Baylor College Of Medicine | Method for treating medical devices using glycerol and an antimicrobial agent |
AU2002367394A1 (en) * | 2001-12-28 | 2003-07-24 | Genzyme Corporation | Bioresorbable foam packing device and use thereof |
AU2003209755B2 (en) * | 2002-02-06 | 2007-11-22 | Ares Trading S.A. | Tumor necrosis factor combined with interferon in demyelinating diseases |
US20070004743A1 (en) * | 2002-02-25 | 2007-01-04 | Xiao Linda L | Intranasal administration of mc4-r agonists |
US20040037809A1 (en) * | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
EP1599474B1 (de) | 2003-03-04 | 2013-04-24 | California Institute Of Technology | Heterocyclische oligomere Verbindungen zur DNS-Erkennung |
BRPI0408491A (pt) * | 2003-03-19 | 2006-04-04 | Ares Trading Sa | tratamento da doença de alzheimer |
FR2864901B1 (fr) | 2004-01-09 | 2007-10-05 | Philippe Perovitch | Composition pour le traitement au contact des hyposialies, incluant de la pilocarpine et a effets multiples |
WO2005071101A1 (en) * | 2004-01-23 | 2005-08-04 | University Hospital Of Basel | Treatment of hepatitis c infection by increasing stat1 methylation |
US20070212306A1 (en) * | 2004-06-07 | 2007-09-13 | Quay Steven C | Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides |
US7776312B2 (en) * | 2004-08-13 | 2010-08-17 | Healthpartners Research Foundation | Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity |
US9216161B2 (en) | 2004-08-13 | 2015-12-22 | Healthpartners Research Foundation | Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity |
US7618615B2 (en) | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
US20090047347A1 (en) * | 2005-07-29 | 2009-02-19 | Aegis Therapeutics, Inc. | Compositions for Drug Administration |
US20060046969A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Antibacterial compositions for drug administration |
US9114069B2 (en) * | 2004-08-25 | 2015-08-25 | Aegis Therapeutics, Llc | Antibacterial compositions for drug administration |
US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
US8642564B2 (en) * | 2004-08-25 | 2014-02-04 | Aegis Therapeutics, Llc | Compositions for drug administration |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
CA2607806A1 (en) * | 2005-05-04 | 2006-11-16 | Nautilus Biotech, S.A. | Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides |
WO2007025249A2 (en) * | 2005-08-26 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
WO2007110231A2 (en) * | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
EP1915986A1 (de) * | 2006-10-23 | 2008-04-30 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Wachstumsfaktorhaltige Lipidformulierungen |
WO2008154337A1 (en) * | 2007-06-08 | 2008-12-18 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
US9707274B2 (en) | 2007-06-08 | 2017-07-18 | Healthpartners Research & Education | Methods for preventing and treating post-traumatic stress disorder (PTSD) |
US8221358B2 (en) * | 2007-11-20 | 2012-07-17 | Warsaw Orthopedic, Inc. | Devices and methods for delivering drug depots to a site beneath the skin |
CA2756690C (en) | 2008-03-28 | 2016-08-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
WO2009143167A2 (en) | 2008-05-19 | 2009-11-26 | Advaxis | Dual delivery system for heterologous antigens |
EP2307036A4 (de) | 2008-06-13 | 2012-08-08 | Wisconsin Alumni Res Found | Neues peptid-adjuvans für die grippeimpfung |
US8129499B2 (en) | 2008-06-13 | 2012-03-06 | Wisconsin Alumni Research Foundation | Antiviral peptides against influenza virus |
US20100106136A1 (en) * | 2008-10-29 | 2010-04-29 | Warsaw Orthopedic, Inc. | Drug delivery device with sliding cartridge |
US9352137B2 (en) * | 2008-10-29 | 2016-05-31 | Warsaw Orthopedic, Inc. | Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover |
US20100106132A1 (en) * | 2008-10-29 | 2010-04-29 | Warsaw Orthopedic, Inc. | Drug cartridge for delivering a drug depot comprising superior and inferior covers |
US20110263580A1 (en) * | 2008-12-11 | 2011-10-27 | Thomas Miller | Method for treating alzheimer's disease and related conditions |
US8440631B2 (en) | 2008-12-22 | 2013-05-14 | Aegis Therapeutics, Llc | Compositions for drug administration |
KR20170124619A (ko) | 2009-03-27 | 2017-11-10 | 아카데미아 시니카 | 바이러스에 대한 면역을 위한 방법 및 조성물 |
WO2011011725A2 (en) | 2009-07-24 | 2011-01-27 | Schultz-Cherry Stacey L | Use of toxoplasma and derived compositions to prevent or treat microbial infections |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
GB0921525D0 (en) * | 2009-12-08 | 2010-01-27 | Isis Innovation | Product and method |
US9468662B2 (en) | 2010-07-12 | 2016-10-18 | Orphit | Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases |
FR2962335B1 (fr) * | 2010-07-12 | 2013-01-18 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives |
WO2012138377A2 (en) | 2010-10-01 | 2012-10-11 | Trustees Of The University Of Pennsylvania | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
AU2012223160B2 (en) | 2011-03-03 | 2016-08-18 | Impel Pharmaceuticals Inc. | Nasal drug delivery device |
CN103687611A (zh) | 2011-03-11 | 2014-03-26 | 阿德瓦希斯公司 | 基于李斯特菌属的佐剂 |
CA2835208C (en) | 2011-05-09 | 2019-08-20 | Impel Neuropharma, Inc. | Nozzles for nasal drug delivery |
US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
WO2012174158A2 (en) | 2011-06-14 | 2012-12-20 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine |
US8987199B2 (en) | 2011-06-15 | 2015-03-24 | Nerve Access, Inc. | Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders |
WO2013134777A1 (en) | 2012-03-09 | 2013-09-12 | Northeastern University | Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders |
SG10201700392UA (en) | 2012-03-12 | 2017-03-30 | Advaxis Inc | Suppressor cell function inhibition following listeria vaccine treatment |
US9033912B2 (en) | 2012-03-28 | 2015-05-19 | Warsaw Orthopedic, Inc. | Drug delivery system |
US20130280297A1 (en) | 2012-04-11 | 2013-10-24 | Lori Neal | Use of toxoplasma gene products to prevent or treat microbial infections |
US10279012B2 (en) | 2013-03-11 | 2019-05-07 | Healthpartners Research & Education | Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin |
CA2909954C (en) | 2013-04-28 | 2021-03-23 | Impel Neuropharma, Inc. | Medical unit dose container |
SG11201509419QA (en) | 2013-05-15 | 2015-12-30 | Univ Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
US9901684B2 (en) | 2013-10-17 | 2018-02-27 | Warsaw Orthopedic, Inc. | Drug delivery device with retaining member |
US10314911B2 (en) | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
WO2015179415A1 (en) | 2014-05-19 | 2015-11-26 | Novartis Ag | Methods of treating anorexia |
US10080877B2 (en) | 2014-07-25 | 2018-09-25 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a drug cartridge |
USD809652S1 (en) | 2014-07-25 | 2018-02-06 | Warsaw Orthopedic, Inc. | Drug delivery device |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
PT3242676T (pt) | 2015-01-07 | 2023-12-06 | TONIX Pharmaceuticals Holding Corp | Formulações de ocitocina que contém magnésio e métodos de uso |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
US10335435B2 (en) | 2015-05-22 | 2019-07-02 | Marco Merida | Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach |
US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
SG10201912761UA (en) | 2016-04-15 | 2020-02-27 | The Trustees Of The Univ Of Pennsyvania | Gene therapy for treating mucopolysaccharidosis type ii |
USD802756S1 (en) | 2016-06-23 | 2017-11-14 | Warsaw Orthopedic, Inc. | Drug pellet cartridge |
US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
CN106620656A (zh) * | 2017-03-03 | 2017-05-10 | 上海唯科生物制药有限公司 | 一种肿瘤坏死因子舌下给药制剂及其制备方法 |
CA3075849A1 (en) | 2017-09-19 | 2019-03-28 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
EP3684938A1 (de) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gentherapie zur behandlung von mukopolysaccharidose typ ii |
WO2019157099A1 (en) | 2018-02-06 | 2019-08-15 | Aegis Therapeutics, Llc | Intranasal epinephrine formulations and methods for the treatment of disease |
WO2019241579A1 (en) | 2018-06-13 | 2019-12-19 | Wisconsin Alumni Research Foundation | Toxoplasma gondii vaccine |
AU2019418744B2 (en) | 2019-01-03 | 2023-08-03 | Impel Pharmaceuticals Inc. | Nasal drug delivery device |
EP4319803A1 (de) | 2021-04-08 | 2024-02-14 | Vaxthera SAS | Coronavirus-impfstoff, der ein mosaikprotein enthält |
WO2023069126A1 (en) | 2021-10-19 | 2023-04-27 | Odyssey Health, Inc. | Breath-powered nasal devices for treatment of traumatic brain injury (tbi), including concussion, and methods and methods |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4462985A (en) | 1980-08-22 | 1984-07-31 | University Of Illinois Foundation | Delivery of biologically active components of heterologous species interferon isolates |
US4479932A (en) * | 1982-05-18 | 1984-10-30 | University Of Florida | Brain-specific drug delivery |
US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
US4820515A (en) | 1982-12-13 | 1989-04-11 | Texas A&M University System | Method of using interferon in low dosage to regulate appetite and efficiency of food utilization |
US4497795A (en) | 1982-12-13 | 1985-02-05 | The Texas A&M University System | Method of regulating appetite and efficiency of food utilization employing interferon |
SU1139444A1 (ru) | 1982-12-15 | 1985-02-15 | Iretskij Andrej N | Способ введени нейротропных и гормональных препаратов |
US4746508A (en) * | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
US4857316A (en) * | 1984-10-03 | 1989-08-15 | Syntex (U.S.A.) Inc. | Synergistic antiviral composition |
IL76591A0 (en) * | 1984-10-05 | 1986-02-28 | Bioferon Biochem Substanz | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4820514A (en) | 1985-12-30 | 1989-04-11 | Texas A&M University System | Low dosage of interferon to enhance vaccine efficiency |
US5811128A (en) * | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
ZA878295B (en) | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
US5017371A (en) | 1988-01-06 | 1991-05-21 | Amarillo Cell Culture Company, Incorporated | Method for reducing side effects of cancer therapy |
US5906816A (en) * | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
GB8918264D0 (en) * | 1989-08-10 | 1989-09-20 | Furnell David | Rotary display unit |
US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
AU6909091A (en) * | 1989-12-05 | 1991-06-26 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
US5215741A (en) | 1990-10-30 | 1993-06-01 | Amarillo Cell Culture Company, Incorporated | Method for prevention of parasite infections |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
CA2094217A1 (en) * | 1992-04-17 | 1993-10-18 | Yasutaka Igari | Transmucosal therapeutic composition |
PT647137E (pt) * | 1992-06-22 | 2008-11-24 | Univ California | Antagonistas dos receptores da glicina e a sua utilização |
JPH0741428A (ja) | 1993-07-30 | 1995-02-10 | Teijin Ltd | ペプチド、蛋白質性薬物経鼻・経肺製剤 |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
US5675942A (en) * | 1995-08-28 | 1997-10-14 | Crawford; Van | Wall panel alignment device and spacer |
CA2253971A1 (en) * | 1996-05-09 | 1997-11-13 | Pharma Pacific Pty.Ltd. | Use of high dose interferon by oralmucosal contact to treat viral infections and neoplastic conditions |
HUP9602024A3 (en) * | 1996-07-25 | 1999-05-28 | Toth Sandor | Pharmaceutical composition containing aminoacid for external use |
US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
AU2173400A (en) * | 1998-12-09 | 2000-06-26 | Chiron Corporation | Method for administering agents to the central nervous system |
DK1031347T3 (da) | 1999-01-27 | 2002-07-08 | Idea Ag | Transnasal transport/immunisering med meget tilpasselige bærere |
-
2000
- 2000-12-08 AU AU20698/01A patent/AU783208B2/en not_active Ceased
- 2000-12-08 CA CA002393688A patent/CA2393688A1/en not_active Abandoned
- 2000-12-08 US US09/733,168 patent/US20010043915A1/en not_active Abandoned
- 2000-12-08 WO PCT/US2000/033220 patent/WO2001041782A2/en active IP Right Grant
- 2000-12-08 AT AT00984018T patent/ATE300952T1/de not_active IP Right Cessation
- 2000-12-08 EP EP00984018A patent/EP1237567B1/de not_active Expired - Lifetime
- 2000-12-08 IL IL15010900A patent/IL150109A0/xx unknown
- 2000-12-08 DE DE60021760T patent/DE60021760T2/de not_active Expired - Fee Related
- 2000-12-08 JP JP2001543126A patent/JP2003516360A/ja active Pending
-
2002
- 2002-03-20 US US10/102,163 patent/US6991785B2/en not_active Expired - Fee Related
- 2002-06-07 NO NO20022731A patent/NO20022731L/no not_active Application Discontinuation
-
2005
- 2005-09-09 US US11/222,669 patent/US20060159626A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2003516360A (ja) | 2003-05-13 |
NO20022731D0 (no) | 2002-06-07 |
US6991785B2 (en) | 2006-01-31 |
AU783208B2 (en) | 2005-10-06 |
IL150109A0 (en) | 2002-12-01 |
US20020141971A1 (en) | 2002-10-03 |
CA2393688A1 (en) | 2001-06-14 |
DE60021760T2 (de) | 2006-06-08 |
WO2001041782A2 (en) | 2001-06-14 |
US20010043915A1 (en) | 2001-11-22 |
DE60021760D1 (de) | 2005-09-08 |
EP1237567A2 (de) | 2002-09-11 |
EP1237567B1 (de) | 2005-08-03 |
NO20022731L (no) | 2002-08-08 |
WO2001041782A3 (en) | 2002-01-17 |
US20060159626A1 (en) | 2006-07-20 |
AU2069801A (en) | 2001-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE300952T1 (de) | Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem | |
WO2005000215A3 (en) | Methods for treating pain | |
ATE254926T1 (de) | Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten. | |
Dahl | Imiquimod: a cytokine inducer | |
JP2003516360A5 (de) | ||
CY1107995T1 (el) | ΑΝΑΣΤΟΛΗ ΔΡΑΣΤΙΚΟΤΗΤΑΣ p38 ΚΙΝΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΡΥΛ ΚΑΙ ΕΤEPΟΑΡΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΤEPΟΚΥΚΛΙΚΕΣ ΟΥΡΙΕΣ | |
CA2236591A1 (en) | Continuous low-dose cytokine infusion therapy | |
BR9814458A (pt) | Composto, composição farmacêutica e método de tratamento de disfunções afetivas | |
NZ212632A (en) | Tumor necrosis factor, its preparation and its use | |
DE69928563D1 (de) | Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystem | |
RU98115594A (ru) | Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах | |
AU2173400A (en) | Method for administering agents to the central nervous system | |
DE60237721D1 (de) | Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen | |
ATE65403T1 (de) | Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit. | |
ZA865735B (en) | Pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration | |
EP0231819A3 (en) | Pharmaceutical agent for the treatment of myelogenous leukemia | |
ATE320270T1 (de) | Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren | |
Naveau et al. | Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment | |
DE60235955D1 (de) | Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen | |
ATE80998T1 (de) | Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems. | |
DE69727222D1 (de) | Zusammensetzung und system zur iontophoretischen transdermalen abgabe von medikamenten | |
DE60023944D1 (de) | Replikationsunfähige herpesvirus-vektoren | |
KR900701311A (ko) | 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 | |
SU1187830A1 (ru) | Способ лечени вирусного гепатита у детей | |
TW202416967A (zh) | 用於治療第1型ifn介導疾病之s1p1受體調節劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |